gr 144053 has been researched along with dx 9065a in 1 studies
| Studies (gr 144053) | Trials (gr 144053) | Recent Studies (post-2010) (gr 144053) | Studies (dx 9065a) | Trials (dx 9065a) | Recent Studies (post-2010) (dx 9065a) |
|---|---|---|---|---|---|
| 21 | 1 | 2 | 92 | 7 | 8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Collen, D; Kozawa, O; Matsuno, H; Matsuo, O; Nishida, M; Uematsu, T; Ueshima, S | 1 |
1 other study(ies) available for gr 144053 and dx 9065a
| Article | Year |
|---|---|
tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor.
Topics: Animals; Bleeding Time; Factor Xa Inhibitors; Fibrinolytic Agents; Indicators and Reagents; Mice; Naphthalenes; Partial Thromboplastin Time; Piperazines; Piperidines; Plasminogen Activators; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Propionates; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 2000 |